retatrutide phase 2 trial new england journal of medicine 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ The Retatrutide Dosage Chart

Many commercial and employer plans cover Wegovy for people who meet criteria related to the drugs approved uses (obesity/overweight, cardiovascular risk reduction, or fatty liver disease)

The GLP-1 and hair thinning connection

The Journal of the American Medical Association recently published diet and exercise guidance for people taking GLP-1s (3): Source: Mehrtash F, Dushay J, Manson JE

If depression is a significant factor in your weight gain, this is explicitly worth discussing with your prescriber when Contrave comes up

Treatment availability, eligibility, and recommendations depend on medical evaluation, health history, current medications, weight loss goals, and provider guidance

Months 7-11: Approaching plateau